mev electron beam  (Institut Curie)

Journal: bioRxiv

Article Title: Targeting STING-ATM axis overcomes radiotherapy-induced immune suppression and restores anti-tumor immunity in nasopharyngeal carcinoma

doi: 10.1101/2025.11.12.687945

Figure Lengend Snippet: RT combined with the STING agonist diABZI enhances therapeutic efficacy and modulates immune responses. ( A) Schematic of the treatment protocol in mouse MTCQ1_Luc2 tumor-bearing C57BL/6 mice treated with diABZI and/or RT. Day 1 indicates the time of tumor cell inoculation. diABZI (2 mg/kg, intraperitoneal) and local tumor RT (6 MV photon or 6 MeV electron beam) were administered as indicated. Tumor progression was monitored using an in vivo bioluminescence imaging system (IVIS). ( B) IVIS images on days 6, and 19 for the indicated treatment groups: untreated, diABZI alone, photon irradiation alone, diABZI + photon irradiation, electron beam alone, and diABZI + electron beam. ( C) Tumor growth curves showing total flux (photons/s) from IVIS measurements. Data are presented as means ± SD. ( D) Tumor burden on day 19 based on total flux. Each dot represents one mouse (n = 7– 8 mice/group; * P < 0.05, ** P < 0.01, *** P < 0.001; Mann–Whitney test). ( E ) Quantification of spleen area (* P < 0.05, *** P < 0.001; Mann–Whitney test). ( F) Heatmaps of cGAS–STING signaling genes in tumors and spleens (P < 0.05, |log2FC| > 1). Data are presented as means of replicates (n = 2 for untreated, n = 3 or 4 for other groups). Red, upregulation; blue, downregulation. ( G ) GSEA in tumors comparing photon versus untreated (left) and diABZI + photon versus photon alone (right). ( H ) GSEA in spleens comparing photon versus untreated (left) and diABZI + photon versus photon alone (right). Red, increased normalized enrichment score (NES); blue, decreased NES. ( I ) Heatmaps of PD-1 pathway genes in tumors and spleens. Data are presented as means of replicates. Red, upregulation; blue, downregulation.

Article Snippet: Fractionated radiotherapy with either 4 Gy 6 MV photon or 6 MeV electron beam irradiation (Trilogy, Varian Medical Systems) was applied to the tumor site on days 8, 16, and 21.

Techniques: Drug discovery, In Vivo, Imaging, Irradiation, MANN-WHITNEY

Journal: bioRxiv

Article Title: Targeting STING-ATM axis overcomes radiotherapy-induced immune suppression and restores anti-tumor immunity in nasopharyngeal carcinoma

doi: 10.1101/2025.11.12.687945

Figure Lengend Snippet: diABZI treatment reduces immune suppression and Treg expansion. ( A ) Heatmaps show coinhibitory and IL-10 signaling signatures in tumor tissues from the indicated groups. Data are presented as means of replicates. Red, upregulation; blue, downregulation. ( B) Quantification of FOXP3 scores in tumors across groups (* P < 0.05, ** P < 0.01, *** P < 0.001; Fisher’s exact test). ( C) Representative IHC images of FOXP3 expression in tumors across all groups. Scale bars, 50 μm. ( D ) Representative IHC images of p-ATM and FOXP3 expression in consecutive tumor sections. Scale bars, 50 μm. ( E) Representative IHC images of FOXP3 and TGFB1 expression in consecutive tumor sections. Scale bars, 50 μm. ( F) Correlation analysis between p-ATM (S1981) and FOXP3 expression in tumors (Spearman’s correlation test). ( G and H ) Immunofluorescence staining for p-ATM (S1984) (green) and FOXP3 (red) in tumors ( G ) and spleens ( H ) from untreated and diABZI + electron beam-treated groups. ( I ) Real-time monitoring of NPC cell growth in response to diABZI stimulation using an xCelligence real-time analyzer. Values represent means and SD of triplicate experiments. Black arrows indicate the time of diABZI addition. ( J ) Western blot analysis of CYLD and phosphorylated IκB (S32) levels in diABZI-treated NPC cells. GAPDH was used as a loading control. ( K ) Immunofluorescence staining of CYLD in NPC cells treated with diABZI (0.3 μM) for 3 hours. F-actin was stained with Alexa Fluor 488 phalloidin (green), and nuclei were counterstained with Hoechst33342 (blue). Scale bars, 20 μm.

Article Snippet: Fractionated radiotherapy with either 4 Gy 6 MV photon or 6 MeV electron beam irradiation (Trilogy, Varian Medical Systems) was applied to the tumor site on days 8, 16, and 21.

Techniques: Expressing, Immunofluorescence, Staining, Western Blot, Control